Bristol-Myers Squibb's Opdivo Fails to Show Superiority to Bayer's Nexavar in Liver Cancer 0 24.06.2019 03:00 Feedity.com The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
